MΦM-coated NPs loaded with SD-208, a TGF-βR1 kinase inhibitor (Mφ-SDNPs) increased the proportion of CTLs in tumor tissue, leading to improved immune response and a strong anticancer effect when combined with anti-PD-1 antibodies 71. Here, PDCD1 is linked to neoplasm.